AI주식인사이트AI Stock Insight
C

코오롱티슈진

950160KOSDAQ기초 의약물질 제조업

52.3 / 100

Reference Date: 2026-06-10

Financial Score18.0 / 40
News Sentiment15.3 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 10.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Koongtishujin is a biotech company developing cell gene therapy drugs using its TG-C platform, currently conducting Phase III clinical trials for knee osteoarthritis and Phase II trials for hip osteoarthritis. As of July 2024, the Phase III trial for knee osteoarthritis has enrolled 1,066 patients. The company also operates a complex distribution business, selling health supplements, cosmetics, and wines through its W-store and L&B segments.

Number of Employees

58people

Average Salary

163.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 27.714.0Point
PBR
—Industry Average 1.743.5Point
ROE
-188.19Industry Average -6.033.5Point

31.2x industry avg (excellent)

Debt Ratio
6.60Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼0.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -77.0% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 1Neutral 4Negative 3Average Sentiment Score 61.2

Detailed Momentum

52-week position6.0Point

52w upper range (64%)

Current 102,900Won52-week high 138,80052-week low 36,300
1-month return1.0Point

1m -10.21% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15
  • Neutral파생상품거래손실발생2026-05-15
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-15